Dissecting Common and Unique Effects of Anti-alpha 4 beta 7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis

摘要

Background and Aims: Vedolizumab is an anti-alpha 4 beta 7 antibody approved for the treatment of ulcerative colitis [UC]. Although it is assumed that vedolizumab blocks intestinal homing of lymphocytes, its effects on different intestinal cell populations are not fully stablished. In order to establish the unique mechanisms of action of vedolizumab in UC patients, we compared its effects to those induced by anti-tumour necrosis factor [TNF].